Effects of HQK-1001 in Patients With Sickle Cell Disease

NCT01601340 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease
Sickle Cell Anemia
Sickle Cell Disorders
Hemoglobin S Disease
Sickling Disorder Due to Hemoglobin S

Interventions

DRUG: HQK-1001
DRUG: Placebo

Sponsor

HemaQuest Pharmaceuticals Inc.